Welcome to the Department of Radiation Oncology
Message from James M. Metz, MD — Chairman
Penn Radiation Oncology is dedicated to a three-part mission of excellence in patient care, basic and translational research, and the education of residents and students. We are committed to delivering excellence in every area and as such we steadfastly believe that "Excellence is Standard."
Penn Radiation Oncology is one of the most comprehensive radiation oncology programs in the world. The outstanding faculty and staff, combined with Penn’s extensive collection of advanced technology, gives patients access to nearly every treatment option available for their cancer. The broad range of radiation treatments available include Proton Therapy, intensity-modulated radiation therapy (IMRT), high-dose rate (HDR) and low-dose rate brachytherapy, partial breast irradiation, stereotactic radiosurgery (SRS), and Gamma Knife radiation. With the Abramson Cancer Center of the University of Pennsylvania, Penn Radiation Oncology provides patient care at the Ruth and Raymond Perelman Center for Advanced Medicine (PCAM), six major hospitals, and nine community-based sites.
Read more of the Message from the Chair »
Dr. Vapiwala named Eli Glatstein Professor »
News
-
ASTRO Members Receive Fellows Designation
Tuesday, August 13, 2024
American Society for Radiation Oncology (ASTRO) has selected 48 members to receive ASTRO fellow designation during the 2024 ASTRO Annual Meeting, including Dimitris N. Mihailidis, PhD, an associate professor of Clinical Radiation Oncology, and Ying Xiao, PhD, a professor of Radiation Oncology.
-
JAK Inhibitors Improve Immune Checkpoint Inhibitors
Friday, August 9, 2024
Two separate clinical trials have found that a class of drugs that stymie inflammation may improve the effectiveness of commonly used immunotherapies. In both trials—one involving people with lung cancer and the other with lymphoma—adding a JAK inhibitor to an immune checkpoint inhibitor shrank tumors in more than half of the participants. Andy Minn, MD, PhD, a professor of Radiation Oncology, who helped to lead the lung cancer study, noted that both studies reached the same conclusion, “which to me is just really remarkable and provides a lot of motivation and hope that we’re on to something.”
-
Five Questions with ASTRO’s President-elect, Neha Vapiwala, MD
Wednesday, August 7, 2024
Neha Vapiwala, MD, the Eli Glatstein endowed professor and vice chair in the department of Radiation Oncology and dean of admissions at the University of Pennsylvania Perelman School of Medicine, is the incoming president of ASTRO. Vapiwala speaks about how her career has prepared her for this role, her top priorities during her term, the importance of other women seeing her at the helm of a national society, and the legacy she hopes to leave on the medical field.